Critical data-based re-evaluation of minocycline as a putative specific microglia inhibitor

GLIA

Volumn 64, Issue 10, 2016, Pages 1788-1794

  Möller, Thomas ^a,b   Bard, Frédérique ^c   Bhattacharya, Anindya ^d   Biber, Knut ^e,f   Campbell, Brian ^a   Dale, Elena ^a   Eder, Claudia ^g   Gan, Li ^h   Garden, Gwenn A ^b   Hughes, Zoë A ⁱ   Pearse, Damien D ^j   Staal, Roland G W ^a   Sayed, Faten A ^h,k   Wes, Paul D ^a   Boddeke, Hendrikus W G M ^f  

^a LUNDBECK RESEARCH USA   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c Janssen Prevention Center Janssen Pharmaceutical Companies of Johnson and Johnson   (United States)

^d JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^e UNIVERSITY OF FREIBURG   (Germany)

^f UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^g ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^h GLADSTONE INSTITUTES   (United States)

ⁱ PFIZER INC   (United States)

^j UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^k UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

inhibitor; lack of specificity; microglia; minocycline

Indexed keywords

MINOCYCLINE;

ANTIINFLAMMATORY ACTIVITY; ASTROCYTE; DATA BASE; HUMAN; MICROGLIA; NONHUMAN; OLIGODENDROGLIA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW;

EID: 84984991273     PISSN: 08941491     EISSN: 10981136     Source Type: Journal    
DOI: 10.1002/glia.23007     Document Type: Review

References (102)

1. Agwuh KN, MacGowan A. 2006. Pharmacokinetics and pharmacodynamics of the tetracyclines including glycylcyclines. J Antimicrob Chemother 58:256–265.
2. Arnoux I, Hoshiko M, Sanz Diez A, Audinat E. 2014. Paradoxical effects of minocycline in the developing mouse somatosensory cortex. Glia 62:399–410.
3. Balestrero S, Ciambellotti A, Parodi A, Rebora A. 2001. Minocycline-induced lupus-like syndrome. Int J Dermatol 40:474–475.
4. Baron U, Bujard H. 2000. Tet repressor-based system for regulated gene expression in eukaryotic cells: Principles and advances. Methods Enzymol 327:401–421.
5. Barza M, Brown RB, Shanks C, Gamble C, Weinstein L. 1975. Relation between lipophilicity and pharmacological behavior of minocycline, doxycycline, tetracycline, and oxytetracycline in dogs. Antimicrob Agents Chemother 8:713–720.
6. Bernardino AL, Kaushal D, Philipp MT. 2009. The antibiotics doxycycline and minocycline inhibit the inflammatory responses to the Lyme disease spirochete Borrelia burgdorferi. J Infect Dis 199:1379–1388.
7. Biber K, Owens T, Boddeke E. 2014. What is microglia neurotoxicity (Not)? Glia 62:841–854.
8. Bonelli RM, Hodl AK, Hofmann P, Kapfhammer HP. 2004. Neuroprotection in Huntington's disease: A 2-year study on minocycline. Int Clin Psychopharmacol 19:337–342.
9. Bostanci N, Akgul B, Tsakanika V, Allaker RP, Hughes FJ, McKay IJ. 2011. Effects of low-dose doxycycline on cytokine secretion in human monocytes stimulated with Aggregatibacter actinomycetemcomitans. Cytokine 56:656–661.
10. Cazalis J, Tanabe S, Gagnon G, Sorsa T, Grenier D. 2009. Tetracyclines and chemically modified tetracycline-3 (CMT-3) modulate cytokine secretion by lipopolysaccharide-stimulated whole blood. Inflammation 32:130–137.
11. Celerier P, Litoux P, Dreno B. 1996. In vitro modulation of epidermal inflammatory cytokines (IL-1 alpha, IL-6, TNF alpha) by minocycline. Arch Dermatol Res 288:411–414.
12. Chen X, Ma X, Jiang Y, Pi R, Liu Y, Ma L. 2011. The prospects of minocycline in multiple sclerosis. J Neuroimmunol 235:1–8.
13. Chopra I, Roberts M. 2001. Tetracycline antibiotics: Mode of action, applications, molecular biology, and epidemiology of bacterial resistance. Microbiol Mol Biol Rev 65:232–260.
14. Clark HW. 1995. Minocycline and rheumatoid arthritis revisited. Ann Intern Med 123:393.
15. Cohen PR. 2004. Medication-associated depersonalization symptoms: Report of transient depersonalization symptoms induced by minocycline. South Med J 97:70–73.
16. Cui Y, Liao XX, Liu W, Guo RX, Wu ZZ, Zhao CM, Chen PX, Feng JQ. 2008. A novel role of minocycline: Attenuating morphine antinociceptive tolerance by inhibition of p38 MAPK in the activated spinal microglia. Brain Behav Immun 22:114–123.
17. Davies MG, Kersey PJ. 1989. Acute hepatitis and exfoliative dermatitis associated with minocycline. BMJ 298:1523–1524.
18. Diguet E, Fernagut PO, Wei X, Du Y, Rouland R, Gross C, Bezard E, Tison F. 2004a. Deleterious effects of minocycline in animal models of Parkinson's disease and Huntington's disease. Eur J Neurosci 19:3266–3276.
19. Diguet E, Gross CE, Tison F, Bezard E. 2004b. Rise and fall of minocycline in neuroprotection: Need to promote publication of negative results. Exp Neurol 189:1–4.
20. Diguet E, Rouland R, Tison F. 2003. Minocycline is not beneficial in a phenotypic mouse model of Huntington's disease. Ann Neurol 54:841–842.
21. Domercq M, Matute C. 2004. Neuroprotection by tetracyclines. Trends Pharmacol Sci 25:609–612.
22. Dunston CR, Griffiths HR, Lambert PA, Staddon S, Vernallis AB. 2011. Proteomic analysis of the anti-inflammatory action of minocycline. Proteomics 11:42–51.
23. Eady EA, Ingham E, Walters CE, Cove JH, Cunliffe WJ. 1993. Modulation of comedonal levels of interleukin-1 in acne patients treated with tetracyclines. J Invest Dermatol 101:86–91.
24. El-Shimy IA, Heikal OA, Hamdi N. 2015. Minocycline attenuates Aβ oligomers-induced pro-inflammatory phenotype in primary microglia while enhancing Aβ fibrils phagocytosis. Neurosci Lett 609:36–41.
25. Fanning WL, Gump DW, Sofferman RA. 1977. Side effects of minocycline: A double-blind study. Antimicrob Agents Chemother 11:712–717.
26. Fraser CL, Biousse V, Newman NJ. 2012. Minocycline-induced fulminant intracranial hypertension. Arch Neurol 69:1067–1070.
27. Furth PA, St Onge L, Boger H, Gruss P, Gossen M, Kistner A, Bujard H, Hennighausen L. 1994. Temporal control of gene expression in transgenic mice by a tetracycline-responsive promoter. Proc Natl Acad Sci USA 91:9302–9306.
28. Galland L. 1995. Minocycline and rheumatoid arthritis revisited. Ann Intern Med 123:392–393.
29. Garden GA, Möller T. 2006. Microglia biology in health and disease. J Neuroimmune Pharmacol 1:127–137.
30. Garrido-Mesa N, Zarzuelo A, Galvez J. 2013. Minocycline: Far beyond an antibiotic. Br J Pharmacol 169:337–352.
31. Golstein PE, Deviere J, Cremer M. 1997. Acute hepatitis and drug-related lupus induced by minocycline treatment. Am J Gastroenterol 92:143–146.
32. Gordon PH, Moore DH, Gelinas DF, Qualls C, Meister ME, Werner J, Mendoza M, Mass J, Kushner G, Miller RG. 2004. Placebo-controlled phase I/II studies of minocycline in amyotrophic lateral sclerosis. Neurology 62:1845–1847.
33. Gordon PH, Moore DH, Miller RG, Florence JM, Verheijde JL, Doorish C, Hilton JF, Spitalny GM, MacArthur RB, Mitsumoto H, Neville HE, Boylan K, Mozaffar T, Belsh JM, Ravits J, Bedlack RS, Graves MC, McCluskey LF, Barohn RJ, Tandan R, Western ALSSG. 2007. Efficacy of minocycline in patients with amyotrophic lateral sclerosis: A phase III randomised trial. Lancet Neurol 6:1045–1053.
34. Gordon PM, White MI, Herriot R, Martin JC, Reid DM. 1995. Minocycline-associated lupus erythematosus. Br J Dermatol 132:120–121.
35. Gossen M, Bujard H. 1992. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc Natl Acad Sci USA 89:5547–5551.
36. Gough A, Chapman S, Wagstaff K, Emery P, Elias E. 1996. Minocycline induced autoimmune hepatitis and systemic lupus erythematosus-like syndrome. BMJ 312:169–172.
37. Greenwald RA, Moak SA, Ramamurthy NS, Golub LM. 1992. Tetracyclines suppress matrix metalloproteinase activity in adjuvant arthritis and in combination with flurbiprofen, ameliorate bone damage. J Rheumatol 19:927–938.
38. Hanada Y, Berbari EF, Steckelberg JM. 2016. Minocycline-induced cutaneous hyperpigmentation in an orthopedic patient population. Open Forum Infect Dis 3:ofv107.
39. Hanisch UK. 2013. Functional diversity of microglia—How heterogeneous are they to begin with? Front Cell Neurosci 7:65.
40. Hanlon LA, Huh JW, Raghupathi R. 2016. Minocycline transiently reduces microglia/macrophage activation but exacerbates cognitive deficits following repetitive traumatic brain injury in the neonatal rat. J Neuropathol Exp Neurol 75:214–226.
41. Hardman CM, Leonard JN, Thomas HC, Goldin R. 1996. Minocycline and hepatitis. Clin Exp Dermatol 21:244–245.
42. Healy J, Alexander B, Eapen C, Roberts-Thomson IC. 2009. Minocycline-induced autoimmune hepatitis. Intern Med J 39:487–488.
43. Hou Y, Xie G, Liu X, Li G, Jia C, Xu J, Wang B. 2016. Minocycline protects against lipopolysaccharide-induced cognitive impairment in mice. Psychopharmacology (Berl) 233:905–916.
44. Huang CY, Chen YL, Li AH, Lu JC, Wang HL. 2014. Minocycline, a microglial inhibitor, blocks spinal CCL2-induced heat hyperalgesia and augmentation of glutamatergic transmission in substantia gelatinosa neurons. J Neuroinflammation 11:7.
45. Huntington Study Group DOMINO Investigators. 2010. A futility study of minocycline in Huntington's disease. Mov Disord 25:2219–2224.
46. Monk E, Shalita A, Siegel DM. 2011. Clinical applications of non-antimicrobial tetracyclines in dermatology. Pharmacol Res 63:130–145.
47. NINDS NET-PD Investigators. 2006. A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease. Neurology 66:664–671.
48. Jain A, Sangal L, Basal E, Kaushal GP, Agarwal SK. 2002. Anti-inflammatory effects of erythromycin and tetracycline on Propionibacterium acnes induced production of chemotactic factors and reactive oxygen species by human neutrophils. Dermatol Online J 8:2.
49. Kauppinen A, Salminen A, Kaarniranta K. 2014. Inflammation as a target of minocycline: Special interest in the regulation of inflammasome signaling. Inflammasome 1:2–14.
50. Keller AF, Gravel M, Kriz J. 2011. Treatment with minocycline after disease onset alters astrocyte reactivity and increases microgliosis in SOD1 mutant mice. Exp Neurol 228:69–79.
51. Kistner A, Gossen M, Zimmermann F, Jerecic J, Ullmer C, Lubbert H, Bujard H. 1996. Doxycycline-mediated quantitative and tissue-specific control of gene expression in transgenic mice. Proc Natl Acad Sci USA 93:10933–10938.
52. Kloppenburg M, Dijkmans BA, Verweij CL, Breedveld FC. 1996. Inflammatory and immunological parameters of disease activity in rheumatoid arthritis patients treated with minocycline. Immunopharmacology 31:163–169.
53. Kloppenburg M, Verweij CL, Miltenburg AM, Verhoeven AJ, Daha MR, Dijkmans BA, Breedveld FC. 1995. The influence of tetracyclines on T cell activation. Clin Exp Immunol 102:635–641.
54. Kobayashi K, Imagama S, Ohgomori T, Hirano K, Uchimura K, Sakamoto K, Hirakawa A, Takeuchi H, Suzumura A, Ishiguro N, et al. 2013. Minocycline selectively inhibits M1 polarization of microglia. Cell Death Dis 4:e525.
55. Koistinaho J, Yrjanheikki J, Kauppinen T, Koistinaho M. 2004. Tetracycline derivatives as anti-inflammatory agents and potential agents in stroke treatment. Ernst Schering Res Found Workshop 47:101–115.
56. Kriz J, Nguyen MD, Julien JP. 2002. Minocycline slows disease progression in a mouse model of amyotrophic lateral sclerosis. Neurobiol Dis 10:268–278.
57. Lander CM. 1989. Minocycline-induced benign intracranial hypertension. Clin Exp Neurol 26:161–167.
58. Ledeboer A, Sloane EM, Milligan ED, Frank MG, Mahony JH, Maier SF, Watkins LR. 2005. Minocycline attenuates mechanical allodynia and proinflammatory cytokine expression in rat models of pain facilitation. Pain 115:71–83.
59. Lefebvre N, Forestier E, Farhi D, Mahsa MZ, Remy V, Lesens O, Christmann D, Hansmann Y. 2007. Minocycline-induced hypersensitivity syndrome presenting with meningitis and brain edema: A case report. J Med Case Rep 1:22.
60. Leite LM, Carvalho AG, Ferreira PL, Pessoa IX, Goncalves DO, Lopes Ade A, Goes JG, Alves VC, Leal LK, Brito GA, et al. 2011. Anti-inflammatory properties of doxycycline and minocycline in experimental models: An in vivo and in vitro comparative study. Inflammopharmacology 19:99–110.
61. Mansuy IM, Bujard H. 2000. Tetracycline-regulated gene expression in the brain. Curr Opin Neurobiol 10:593–596.
62. Matsuura T, Shimizu Y, Fujimoto H, Miyazaki T, Kano S. 1992. Minocycline-related lupus. Lancet 340:1553.
63. Mika J, Osikowicz M, Makuch W, Przewlocka B. 2007. Minocycline and pentoxifylline attenuate allodynia and hyperalgesia and potentiate the effects of morphine in rat and mouse models of neuropathic pain. Eur J Pharmacol 560:142–149.
64. Milano S, Arcoleo F, D'Agostino P, Cillari E. 1997. Intraperitoneal injection of tetracyclines protects mice from lethal endotoxemia downregulating inducible nitric oxide synthase in various organs and cytokine and nitrate secretion in blood. Antimicrob Agents Chemother 41:117–121.
65. Miyachi Y, Yoshioka A, Imamura S, Niwa Y. 1986. Effect of antibiotics on the generation of reactive oxygen species. J Invest Dermatol 86:449–453.
66. Möller T. 2010. Neuroinflammation in Huntington's disease. J Neural Transm (Vienna) 117:1001–1008.
67. Nikodemova M, Watters JJ, Jackson SJ, Yang SK, Duncan ID. 2007. Minocycline down-regulates MHC II expression in microglia and macrophages through inhibition of IRF-1 and protein kinase C (PKC)alpha/betaII. J Biol Chem 282:15208–15216.
68. Ochsendorf F. 2010. Minocycline in acne vulgaris: Benefits and risks. Am J Clin Dermatol 11:327–341.
69. Osikowicz M, Skup M, Mika J, Makuch W, Czarkowska-Bauch J, Przewlocka B. 2009. Glial inhibitors influence the mRNA and protein levels of mGlu2/3, 5 and 7 receptors and potentiate the analgesic effects of their ligands in a mouse model of neuropathic pain. Pain 147:175–186.
70. Pang T, Wang J, Benicky J, Saavedra JM. 2012. Minocycline ameliorates LPS-induced inflammation in human monocytes by novel mechanisms including LOX-1, Nur77 and LITAF inhibition. Biochim Biophys Acta 1820:503–510.
71. Papa S, Caron I, Erba E, Panini N, De Paola M, Mariani A, Colombo C, Ferrari R, Pozzer D, Zanier ER, et al. 2016. Early modulation of pro-inflammatory microglia by minocycline loaded nanoparticles confers long lasting protection after spinal cord injury. Biomaterials 75:13–24.
72. Pontieri FE, Ricci A, Pellicano C, Benincasa D, Buttarelli FR. 2005. Minocycline in amyotrophic lateral sclerosis: A pilot study. Neurol Sci 26:285–287.
73. Porter D, Harrison A. 2003. Minocycline-induced lupus: A case series. N Z Med J 116:U384.
74. Raghavendra V, Tanga F, DeLeo JA. 2003. Inhibition of microglial activation attenuates the development but not existing hypersensitivity in a rat model of neuropathy. J Pharmacol Exp Ther 306:624–630.
75. Redin GS. 1966. Antibacterial activity in mice of minocycline, a new tetracycline. Antimicrob Agents Chemother (Bethesda) 6:371-376.
76. Sadarangani SP, Estes LL, Steckelberg JM. 2015. Non-anti-infective effects of antimicrobials and their clinical applications: A review. Mayo Clin Proc 90:109–127.
77. Sakai N. 2014. Principles for the use of in vivo transgene techniques: Overview and an introductory practical guide for the selection of tetracycline-controlled transgenic mice. Methods Mol Biol 1142:33–40.
78. Sapadin AN, Fleischmajer R. 2006. Tetracyclines: Nonantibiotic properties and their clinical implications. J Am Acad Dermatol 54:258–265.
79. Scheuer T, Brockmoller V, Blanco Knowlton M, Weitkamp JH, Ruhwedel T, Mueller S, Endesfelder S, Buhrer C, Schmitz T. 2015. Oligodendroglial maldevelopment in the cerebellum after postnatal hyperoxia and its prevention by minocycline. Glia 63:1825–1839.
80. Schlienger RG, Bircher AJ, Meier CR. 2000. Minocycline-induced lupus. A systematic review. Dermatology 200:223–231.
81. Schmitz T, Endesfelder S, Chew LJ, Zaak I, Buhrer C. 2012. Minocycline protects oligodendroglial precursor cells against injury caused by oxygen-glucose deprivation. J Neurosci Res 90:933–944.
82. Scholz R, Sobotka M, Caramoy A, Stempfl T, Moehle C, Langmann T. 2015. Minocycline counter-regulates pro-inflammatory microglia responses in the retina and protects from degeneration. J Neuroinflammation 12:209.
83. Shapira L, Soskolne WA, Houri Y, Barak V, Halabi A, Stabholz A. 1996. Protection against endotoxic shock and lipopolysaccharide-induced local inflammation by tetracycline: Correlation with inhibition of cytokine secretion. Infect Immun 64:825–828.
84. Silva Bastos LF, Pinheiro de Oliveira AC, Magnus Schlachetzki JC, Fiebich BL. 2011. Minocycline reduces prostaglandin E synthase expression and 8-isoprostane formation in LPS-activated primary rat microglia. Immunopharmacol Immunotoxicol 33:576–580.
85. Stirling DP, Khodarahmi K, Liu J, McPhail LT, McBride CB, Steeves JD, Ramer MS, Tetzlaff W. 2004. Minocycline treatment reduces delayed oligodendrocyte death, attenuates axonal dieback, and improves functional outcome after spinal cord injury. J Neurosci 24:2182–2190.
86. Thomas M, Ashizawa T, Jankovic J. 2004. Minocycline in Huntington's disease: A pilot study. Mov Disord 19:692–695.
87. Tikka T, Fiebich BL, Goldsteins G, Keinanen R, Koistinaho J. 2001. Minocycline, a tetracycline derivative, is neuroprotective against excitotoxicity by inhibiting activation and proliferation of microglia. J Neurosci 21:2580–2588.
88. Tikka TM, Koistinaho JE. 2001. Minocycline provides neuroprotection against N-methyl-D-aspartate neurotoxicity by inhibiting microglia. J Immunol 166:7527–7533.
89. Tilakaratne A, Soory M. 2014. Anti-inflammatory Actions of Adjunctive Tetracyclines and Other Agents in Periodontitis and Associated Comorbidities. Open Dent J 8:109–124.
90. Toussirot E, Despaux J, Wendling D. 1997. Do minocycline and other tetracyclines have a place in rheumatology? Rev Rhum Engl Ed 64:474–480.
91. Tsuji M, Wilson MA, Lange MS, Johnston MV. 2004. Minocycline worsens hypoxic-ischemic brain injury in a neonatal mouse model. Exp Neurol 189:58–65.
92. US National Institutes of Health. Available at: https://clinicaltrials.gov/ct2/results?term=minocycline&Search=Search.
93. Van Den Bosch L, Tilkin P, Lemmens G, Robberecht W. 2002. Minocycline delays disease onset and mortality in a transgenic model of ALS. Neuroreport 13:1067–1070.
94. van Steensel MA. 2004. Why minocycline can cause systemic lupus—A hypothesis and suggestions for therapeutic interventions based on it. Med Hypotheses 63:31–34.
95. Weller M, Klockgether T. 1998. Minocycline-induced benign intracranial hypertension. J Neurol 245:55.
96. Yang L, Sugama S, Chirichigno JW, Gregorio J, Lorenzl S, Shin DH, Browne SE, Shimizu Y, Joh TH, Beal MF, et al. 2003. Minocycline enhances MPTP toxicity to dopaminergic neurons. J Neurosci Res 74:278–285.
97. Yune TY, Lee JY, Jung GY, Kim SJ, Jiang MH, Kim YC, Oh YJ, Markelonis GJ, Oh TH. 2007. Minocycline alleviates death of oligodendrocytes by inhibiting pro-nerve growth factor production in microglia after spinal cord injury. J Neurosci 27:7751–7761.
98. Zabad RK, Metz LM, Todoruk TR, Zhang Y, Mitchell JR, Yeung M, Patry DG, Bell RB, Yong VW. 2007. The clinical response to minocycline in multiple sclerosis is accompanied by beneficial immune changes: A pilot study. Mult Scler 13:517–526.
99. Zemke D, Majid A. 2004. The potential of minocycline for neuroprotection in human neurologic disease. Clin Neuropharmacol 27:293–298.
100. Zhang Y, Metz LM, Yong VW, Bell RB, Yeung M, Patry DG, Mitchell JR. 2008. Pilot study of minocycline in relapsing-remitting multiple sclerosis. Can J Neurol Sci 35:185–191.
101. Zhu S, Stavrovskaya IG, Drozda M, Kim BY, Ona V, Li M, Sarang S, Liu AS, Hartley DM, Wu DC, et al. 2002a. Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice. Nature 417:74–78.
102. Zhu Z, Zheng T, Lee CG, Homer RJ, Elias JA. 2002b. Tetracycline-controlled transcriptional regulation systems: Advances and application in transgenic animal modeling. Semin Cell Dev Biol 13:121–128.